Company Description
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China.
It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.
The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements.
Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China.
Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.
| Country | China |
| Founded | 1998 |
| IPO Date | Mar 23, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 225 |
| CEO | Gang Lai |
Contact Details
Address: 265, Jingjiu Avenue, Jinggangshan Eco & Tech Dev Zn Ji'An, 343100 China | |
| Phone | 86 79 6840 3309 |
| Website | universe-pharmacy.com |
Stock Details
| Ticker Symbol | UPC |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001809616 |
| CUSIP Number | G9442G104 |
| ISIN Number | KYG9442G1120 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gang Lai | Chief Executive Officer and Chairman |
| Lin Yang | Chief Financial Officer and Director |
| Baochang Liu | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | 6-K | Report of foreign issuer |
| Nov 1, 2024 | 6-K | Report of foreign issuer |
| Oct 10, 2024 | 6-K | Report of foreign issuer |
| Sep 27, 2024 | 6-K | Report of foreign issuer |
| Sep 20, 2024 | 6-K | Report of foreign issuer |
| Sep 3, 2024 | 6-K | Report of foreign issuer |
| Jul 18, 2024 | 6-K | Report of foreign issuer |
| Jun 25, 2024 | 424B4 | Prospectus |
| Jun 7, 2024 | EFFECT | Notice of Effectiveness |
| May 14, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |